Progyny, Inc. (NASDAQ:PGNY) Receives $27.91 Average Target Price from Analysts
by Amy Steele · The Cerbat GemProgyny, Inc. (NASDAQ:PGNY – Get Free Report) has received a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $27.9091.
Several equities analysts have commented on PGNY shares. BTIG Research lowered their price target on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a report on Wednesday, January 21st. Canaccord Genuity Group lowered their price target on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a report on Wednesday, March 11th. Finally, Citizens Jmp upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a report on Tuesday, January 20th.
Get Our Latest Stock Report on Progyny
Progyny Price Performance
PGNY stock opened at $18.17 on Friday. Progyny has a 12 month low of $16.10 and a 12 month high of $28.75. The firm has a 50 day moving average of $18.17 and a two-hundred day moving average of $21.77. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 27.95, a P/E/G ratio of 1.05 and a beta of 0.99.
Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. During the same quarter last year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts expect that Progyny will post 1.12 EPS for the current fiscal year.
Insider Buying and Selling
In other Progyny news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 7,455 shares of company stock valued at $129,515. Insiders own 9.90% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Progyny in the 4th quarter worth approximately $25,000. Federated Hermes Inc. increased its position in Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after buying an additional 819 shares during the period. Hantz Financial Services Inc. increased its position in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares during the period. Versant Capital Management Inc increased its position in Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after buying an additional 894 shares during the period. Finally, Covestor Ltd increased its position in Progyny by 164.9% in the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock worth $56,000 after buying an additional 1,624 shares during the period. 94.93% of the stock is owned by institutional investors.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.